U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Sat Jun 26 18:21:22 UTC 2021
Edited
by admin
on Sat Jun 26 18:21:22 UTC 2021
Protein Type MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type IGG1|TOXIN CONJUGATE
Sequence Origin MOUSE CHIMERIC
Sequence Type COMPLETE
Record UNII
7XL5ISS668
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BRENTUXIMAB VEDOTIN
DASH   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
BRENTUXIMAB VEDOTIN [VANDF]
Common Name English
SGN-35
Code English
BRENTUXIMAB VEDOTIN (GENETICAL RECOMBINATION)
JAN  
Official Name English
BRENTUXIMAB VEDOTIN [WHO-DD]
Common Name English
BRENTUXIMAB VEDOTIN [USAN]
Common Name English
BRENTUXIMAB VEDOTIN [PURPLE BOOK, CDER]
Common Name English
BRENTUXIMAB [VANDF]
Common Name English
MAB CHIMERIC (IGG1) ANTI P28908 (TNR8_HUMAN) (SGN-35)
Common Name English
CAC10-VCMMAE
Code English
ADCETRIS
Brand Name English
BRENTUXIMAB VEDOTIN [JAN]
Common Name English
BRENTUXIMAB VEDOTIN [INN]
Common Name English
BRENTUXIMAB VEDOTIN [MART.]
Common Name English
BRENTUXIMAB VEDOTIN [MI]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1512
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
EU-Orphan Drug EU/3/11/939
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
FDA ORPHAN DRUG 362611
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
WHO-VATC QL01XC12
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
LIVERTOX 121
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
FDA ORPHAN DRUG 521716
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
FDA ORPHAN DRUG 404913
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
FDA ORPHAN DRUG 235606
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
FDA ORPHAN DRUG 656818
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
EMA ASSESSMENT REPORTS ADCETRIS (AUTHORIZED: LYMPHOMA, NON-HODGKIN)
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
FDA ORPHAN DRUG 394013
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
FDA ORPHAN DRUG 536516
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
FDA ORPHAN DRUG 550916
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
EMA ASSESSMENT REPORTS ADCETRIS (AUTHORIZED: HODGKIN DISEASE)
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
FDA ORPHAN DRUG 528716
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
FDA ORPHAN DRUG 268908
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
NDF-RT N0000182967
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
WHO-ATC L01XC12
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
FDA ORPHAN DRUG 418713
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
NCI_THESAURUS C129823
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
Code System Code Type Description
LACTMED
Brentuximab Vedotin
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY
EVMPD
SUB32397
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY
DRUG BANK
DB08870
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY
NCI_THESAURUS
C66944
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY
WIKIPEDIA
BRENTUXIMAB VEDOTIN
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY
INN
9144
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY
MERCK INDEX
M2645
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY Merck Index
MESH
C547738
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY
NDF-RT
N0000182966
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY CD30-directed Antibody Interactions [MoA]
IUPHAR
6772
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY
ChEMBL
CHEMBL1742994
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY
CAS
914088-09-8
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY
RXCUI
1147320
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
4964
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY
FDA UNII
7XL5ISS668
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY
JAPANESE REVIEW
ADCETRIS
Created by admin on Sat Jun 26 18:21:22 UTC 2021 , Edited by admin on Sat Jun 26 18:21:22 UTC 2021
PRIMARY APPROVED JANUARY 2014
From To
1_22 1_96
1_144 1_200
1_220 3_218
1_226 2_226
1_229 2_229
1_261 1_321
1_367 1_425
2_22 2_96
2_144 2_200
2_220 4_218
2_261 2_321
2_367 2_425
3_23 3_92
3_138 3_198
4_23 4_92
4_138 4_198
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_297
N 2_297
Related Record Type Details
CONJUGATE COMPONENT->CONJUGATE
TARGET->CONJUGATED TOXIN
The Kd for the 3 lots ranged from 1.92 +/- 0.77 to 2.64 +/- 0.94 nM. The Kd for the cAC10, the unconjugated antibody, was 1.38.
BINDING
Kd
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE ACTIVE -> PARENT
Addition of E64d, a cysteine protease inhibitor, blocked the release of MMAE
FECAL; URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL
Molecular Formula CHEMICAL